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Pseudomonas aeruginosa is one of the most important nosocomial pathogens,
while other Pseudomonas spp. are occasional causes of infections. Current isolates
of P. aeruginosa are often multiresistant to many classes of potent antimicrobial
agents, including β-lactams, aminoglycosides, and fluoroquinolones. Carba-
penems are the most potent β-lactams, which are active even against extended-
spectrum β-lactamase- and AmpC β-lactamase-producing gram-negative bacilli.
Due to acquired metallo-β-lactamase (MBL) production, however, carbapenem
resistance in P. aeruginosa and Pseudomonas spp., has increasingly been reported
in some countries.
1,2 Richet et al.
3 initiated an international network and included
carbapenemase-producing gram-negative bacilli in the early warning system list
for emerging antimicrobial drug-resistant pathogens. 
The Korean Nationwide Surveillance of Antimicrobial Resistance (KONSAR)
program conducted in the years between 1998 and 2003 showed that P. aeru-
ginosa ranked the 3rd by the number of isolates.
4,5 The imipenem resistance rate of
P. aeruginosa in 1999 was already relatively high (19%), but the rate rose further
to reach 24% in 2004. Two previous studies with clinical isolates of P. aeruginosa,
which were collected in 2000-2001 and in 2003 from hospitals participating in the
program of KONSAR, showed that over 10% of all imipenem-resistant isolates
were VIM-2 type MBL producers.
6,7 Other studies also documented the presence
of MBL-producing P. aeruginosa in Korean hospitals
8,9 as well as the occasional
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presence of VIM-2-type MBL-producing isolates of
Enterobacteriaceae.
10,11 Moreover, the emergence of IMP-1-
like-producing P. aeruginosa and finding of the fifth MBL,
SIM-1-producing Acinetobacter baumannii isolates, were
reported from a hospital in Seoul.
12
The aim of this study was to determine any change in the
prevalence of VIM-2- and IMP-1-like-producing clinical
isolates of Pseudomonas spp. and possible emergence of
new MBL variants two years after the second nationwide
study. The possible presence of MBL-producing Enterobac-
teriaceae and spreading of blaSIM-1 type MBL gene to
Pseudomonas spp. were also investigated.   
Bacterial strains and susceptibility testing
Non-duplicate, imipenem-resistant strains of P. aeruginosa,
Pseudomonas spp., and Enterobacteriaceae, isolated during
January to August 2005, were collected from 23 hospitals
and one commercial laboratory participating in the KONSAR
program. The number of isolates collected from any one
hospital was limited to 25 for an individual species. Identifi-
cation of the species was reconfirmed at the coordinating
laboratory through the use of a conventional method
13,14 or
the ATB 32GN system (bioMerieux, Marcy l’Etoile, France).
The MICs of antimicrobial agents for MBL-producing
isolates were determined by the NCCLS agar dilution
method.
15
Screening MBL-producing isolates  
Carbapenemase production was screened by the imipenem-
disk Hodge (cloverleaf) test, using MacConkey agar instead
of previously used Mueller-Hinton agar.
16 MBL production
was screened by the double-disk synergy test using an
imipenem disk and an EDTA (750 µg) plus sodium mercap-
toacetic acid (SMA, 2 mg) disk on Mueller-Hinton agar
with 10 mm distance from the edge to the edge of the disk.
16
Commercial imipenem disks and media (Becton-Dickinson,
Sparks, MD, USA) were used for these tests, while the
EDTA-SMA disks were prepared from commercially avail-
able chemicals (Sigma Chemical, St. Louis, MO, USA).
MBL gene detection by PCR
To detect alleles of blaIMP-1, blaVIM-2, and blaSIM-1, DDS-
positive isolates were tested by PCR as described previo-
usly.
12 Briefly, primers used were: IMP1-F 5′ -CAT GGT
TTG GTG GTT CTT GT-3′and IMP1-R 5′ -ATA ATT
TGG CGG ACT TTG GC-3′ ; VIM2-F 5′ -ATG TTC
AAA CTT TTG AGT AAG-3′ and VIM2-R 5′ -CTA CTC
AAC GAC TGA GCG-3′ ; SIM1-F 5′ -TAC AAG GGA
TTC GGC ATC G-3′and SIM1-R 5′ -TAA TGG CCT
GTT CCC ATG TG-3′ . PCR was performed with 1µL of
heat-extracted DNA template, 20 pmol of each primer, and
PreMix (Bioneer, Cheongwon, Korea) containing 1 U of
Taq DNA polymerase in a total volume of 20 µL. A Master-
cycler instrument (Eppendorf, Hamburg, Germany) was
used with the following reaction conditions: 94˚C for 5 min,
25 cycles of 94˚C for 30 s, 56˚C for 30 s, and 72˚C for 45 s,
and finally, 72˚C for 7 min. Amplicons were visualized by
electrophoresis and ethidium bromide staining.
Pulsed field gel electrophoresis and MBL gene sequencing
For PFGE, χ baI-digested genomic DNA was prepared
according to the instruction of Bio-Rad (Hercules, Calif.,
USA), and fragments were separated using a CHEF-DR II
system (Bio-Rad). We selected 17 isolates which represented
PFGE types and performed the sequencing of PCR
amplicons using IMP1-F or VIM2-F and Int2 (5′ -AAG
CAG ACT TGA CCT GA-3′ ), and IMP1-R or VIM2-R
and Int1 (5′ -GGC ATC CAA GCA GCA AG-3′ ).
Among the 443 imipenem-resistant isolates collected, the
majority were P. aeruginosa (93.7%), whereas 16 isolates
were species of Enterobacteriaceae (9 K. pneumoniae, 2
each of E. aerogenes, E. coli, and P. mirabilis, and 1 C.
freundii). Of these isolates, 127 were positive for the
imipenem-disk Hodge test and 53 were positive for the DDS
test (Table 1). Alleles of blaVIM-2 or blaIMP-1 were detected in
all 53 DDS-positive isolates. Among all the isolates tested,
the MBL-positive isolates comprised 10.8% of P. aeruginosa
and 66.7% (8 of 12) of P. putida. MBL was not detected in
MATERIALS AND METHODS
RESULTS
Table 1. Metallo-β -Lactamase Genes Detected in Imipenem-Resistant Isolates of Pseudomonas spp. and Enterobacteriaceae 
by PCR
Organism No. of isolates
No. of isolates
No. (%) of isolates positive for
(No. of isolates Hodge test
DDS positive blaVIM-2
blaVIM-2-
blaIMP-1
blaIMP-1-
blaIMP-6
Total
tested) positive like like
P. aeruginosa (415) 117 45 7 25 0 10 3 45 (10.8)
P. putida (12) 10 8 7 0 1 0 0 8 (66.7)
Total (427)  127 53 14 25 1 10 3 53 (12.0)
PCR, polymerase chain reaction; DDS, double disk synergy. MBL-Producing Gram-Negative Bacilli in Korea
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any of the 16 isolates of Enterobacteriaceae.
Overall, the proportion of blaVIM-2 allele-positive isolates
was greater (73.6%) than blaIMP-1 allele-positive isolates
(Table 1). blaSIM-1-allele-positive isolate was not detected.
All MBL-producing isolates of Pseudomonas spp. other
than P. aeruginosa were identified as P. fluorescens/P.
putida by the ATB 32 GN system. However, they were
confirmed to have biochemical characteristics of P. putida
by conventional tests. Nucleotide sequencing revealed that
all the blaVIM-2-like and blaIMP-1-like in P. aeruginosa were
VIM-2 and IMP-6. MBLs in P. putida were identified as
VIM-2 and IMP-1. We found 13 different PFGE patterns in
23 blaVIM-2-like Pseudomonas spp. and 4 patterns in 7 blaIMP-1-
like Pseudomonas spp., indicating that multiple MBL-pro-
ducing Pseudomonas clones exist in Korea. The MIC50s of
various β-lactams for MBL-producing P. aeruginosa were
equal to over 64 µg/mL except that of aztreonam (Table 2).
The % resistances for aztreonam, piperacillin, amikacin,
ciprofloxacin and other β-lactams were 67%, 83%, 87%,
96%, and 100%, respectively.
MBL-producing isolates were detected in 18 of 24 (75%)
hospitals/laboratory, as well as in all four regions (Table 3).
MBL-producing isolates were mostly derived from speci-
mens of urine, sputum, and wounds (Table 4). All 8 MBL-
producing P. putida isolates came either from urine or
sputum. The MBL-producers were isolated mainly from
inpatients (80: 63% isolates from general ward and 17%
isolates from intensive-care unit); while 20% of isolates
were from outpatient department.
Table 2.Antimicrobial Activities Against MBL-Producing P. aeruginosaand P. putida Strains
P. aeruginosa (n = 27) P. putida (n = 7)
Antimicrobial agent MIC (µg/mL)
%R
MIC (µg/mL)
%R
50% of strains 90% of strains Range
Piperacillin > 128 > 128 83 128 - > 128 100
Ceftazidime 128 > 128 100 32 - > 128 100
Cefotaxime > 128 > 128 100 > 128 100
Aztreonam 32 64 67 16 - 64 100
Imipenem 64 > 128 100 32 - > 128 100
Meropenem > 128 > 128 100 64 - > 128 100
Gentamicin > 128 > 128 100 128 - > 128 100
Amikacin > 128 > 128 87 2 - > 128 83
Tobramycin > 128 > 128 100 16 - 128 100
Ciprofloxacin 32 64 96 8 - > 128 100
MBL, metallo- -lactamase.
Table 3. Metallo- -Lactamase Genes Detected in Isolates of Pseudomonas spp. by the Location of Hospitals
No. of isolates tested /  No. of isolates/No. of hospitals positive for:
No. of hospitals participated* blaVIM-2-like blaIMP-1-like Total (% of hospitals)
�
North (244 / 14) 27 / 10 4 / 3  31 / 10 (71.4)
Southeast (83 / 5) 4 / 3  8 / 3  12 / 4 (80.0)
Southwest (68 / 3) 5 / 1  1 / 1 6 / 2 (66.7)
Southwestern island (11 / 1) 1 / 1  0 / 0  1 / 1 (100)
Commercial Lab. (21 / 1) 2 / 1 1 / 1 3 / 1 (100)
Total (427 / 24) 39 / 16  14 / 8  53 / 18 (75.0)
*City or province: North, Seoul, Gyunggi and Gangwon; Southeast, Busan, Daegu, Wulsan and Gyungsang; Southwest, Jeolla; 
Southwestern island, Jeju; Commercial Laboratory collected specimens from clinics located all over the country.    
�Some hospitals had isolates with blaVIM-2and with blaIMP-1.
Table 4. Source of Isolation of Metallo- -Lactamase Gene-Positive Pseudomonasspp.
MBL gene
No. (%) of isolates from:
Urine Sputum Wound Blood Peritoneal  fluid Others Total
blaVIM-2-like 27 3 6 1 1 1 39  (73.6)
blaIMP-1-like 6 2 0 0 0 6 14 (26.4)
Total 33 (62.3) 5 (9.4) 6 (11.3) 1 (1.9) 1 (1.9) 7 (13.2) 53 (100)Antimicrobial resistance surveillance has become increa-
singly important with the recent increase in the resistant
organisms.
17 Analysis of the data generated by the participa-
ting hospitals in 1998 and 2004 showed an alarming rise in
the imipenem resistance rates of P. aeruginosa; from 19%
to 24%.
4,5 Decrease of carbapenem susceptible P. aeruginosa
was also reported in Japan; from 80.7% to 62.0% over the
period of 1998-2002.
18
Among the β-lactamases, the genetically mobile MBL
are among the most feared, because of their ability to hyd-
rolyze virtually all β-lactams, except monobactams,
19 and to
spread horizontally. As a result of their geographic spread,
these enzymes are among the greatest concerns to the
medical communities.
1,20 The rates of occurrence and number
of enzyme types of MBL have escalated since 2000 in Asia,
Europe, and Latin America.
1,2,21 In the present study, 10.8%
of imipenem-resistant-isolates of P. aeruginosa were MBL
producers. These proportions were similar to those in the
previous study in 2000-2001 and in 2003.
6,7 The rate was
also similar to that in a Japanese study in 1998-2002.
18
In this study, only 12 imipenem-resistant isolates of Pseu-
domonas spp. other than P. aeruginosa were collected. It is
of an interest to note that all 8 MBL-producing isolates
were identified as P. putida. P. putida is a species difficult
to differentiate from P. fluorescens by commonly used
biochemical tests. Although P. putida is an only organism
occasionally isolated from clinical specimens,
13 the detection
of MBL gene in 8 of 12 imipenem-resistant isolates suggests
that this organism may play a significant role as an impor-
tant reservoir of MBL genes.
Only 16 imipenem-resistant Enterobacteriaceae isolates
could be collected in this study, and MBL was not detected
in any of these isolates. This indicates rarity of Enterobac-
teriaceae isolates not only producing MBL, but also resistant
to imipenem. MBL has been detected only in a few isolates
of Enterobacteriaceae in Korea.
11,13,22
It is interesting that the first acquired MBL discovered in
the early 1990s was IMP-1 in nearby Japan,
23 whereas in
Korea, VIM-2 was the first MBL type detected and IMP-1
was detected in Acinetobacter spp. in the early 2000s.
6 In a
study at a hospital in Seoul, IMP-1-like-producing P. aeru-
ginosa was detected in strains isolated in 2003-2004, but the
number was only two of 76 isolates of Pseudomonas spp.
12
In the present study, 14 of 53 MBL-producing isolates of P.
aeruginosa and P. putida had blaIMP-1, indicating spread of
this MBL gene to these species (Table 1). However, blaSIM-1
which was discovered in A. baumannii isolates in Seoul has
not yet spread to Pseudomonas spp. 
Detection of MBL-producing Pseudomonas spp. in iso-
lates collected from 18 of 24 (75.0%) hospitals/laboratory in
the present study (Table 3) is a great concern. As in previous
studies,
6,7 MBL-producing isolates were isolated mostly
from urine and sputum specimens (Table 4), indicating that
these specimens can serve as the important reservoirs for
dissemination of the resistant organisms. 
In conclusion, clinical isolates of P. aeruginosa in Korea
are increasingly resistant to imipenem, and a significant
proportion of the resistance is due to MBL production.
blaVIM-2 remains the dominant type, however, IMP-1 variant,
IMP-6-producing P. aeruginosa emerged. Extensive amount
of effort is required to control further spread of MBL-pro-
ducing Pseudomonas spp. in hospitals. 
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